CG Oncology: The Million-Dollar Bet on the Bladder Cancer Breakthrough

CG Oncology is a late-stage biopharma company focusing on the development of a bladder-preserving immunotherapy called Cretostimogene . With liquid assets of around $1 billion, the operational business is fully funded until 2029 without the immediate risk of dilution from emergency capital increases. The value of the stock largely depends on the success of the anticipated FDA approval application in the fourth quarter of 2026, which, if approved, will mark the transition from research to commercial distribution. There are stories on the...